Chih-Yi Weng, chairlady and CEO of Charsire Biotechnology, one of Taiwan’s leading biotech companies focused on the development of botanical new drugs as well as topical and personal care products, provides insights into the company’s unique business model and its promising and maturing R&D pipeline, while Charsire was ranked in 2015 by Deloitte as one of the fastest growing life sciences companies in Asia Pacific.
Could you introduce Charsire Biotechnology to our international readers and document the vision that has been driving its development since the company’s creation, in 2002?
"Our business model and development approach are very different from these of most other Taiwanese biotech companies, which usually exclusively rely on the stock market and institutional investors to move their R&D pipeline forward."
